Joseph Buscema, MD
Gynecologic Oncology · Tucson, AZNPI 1891764502
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. GSK accounts for 61.2% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2024 at $3,122 and has fallen 79.5% since, to $639 in 2025.
Across 141 payments — averaging $58.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- AstraZeneca$748
- Merck$384
- Stryker$349
- Daiichi Sankyo Inc.$205
- Myriad Genetic Laboratories, Inc.$179
- plus $1K from 28 others
Across 1,216 payments — averaging $4605.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.5M
- Merck$1.3M
- Pfizer$984K
- Novartis$443K
- Daiichi Sankyo Inc.$322K
- Genentech, Inc.$263K
- plus $725K from 10 others
What the payments were for
- Consulting fees$4,77558%
- Travel & lodging$3494%
- Food & beverage$3,04837%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $5,004 |
| AstraZeneca | 31 | $748 |
| Merck | 23 | $384 |
| Stryker | 1 | $349 |
| Daiichi Sankyo Inc. | 3 | $205 |
| Myriad Genetic Laboratories, Inc. | 1 | $179 |
| Eisai Inc. | 6 | $122 |
| Gilead | 6 | $122 |
| Novartis | 5 | $117 |
| AbbVie | 5 | $103 |
| Genmab U.S., Inc. | 3 | $87 |
| Bristol Myers Squibb | 3 | $77 |
| Intuitive Surgical | 2 | $71 |
| Pfizer | 4 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Johnson & Johnson | 4 | $56 |
| Pharmacosmos Therapeutics Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $40 |
| Exelixis Inc. | 2 | $34 |
| Cardinal Health 414 LLC | 1 | $29 |
| Incyte Corporation | 2 | $25 |
| Caris MPI, Inc. | 1 | $25 |
| Amgen | 2 | $24 |
| Sanofi | 1 | $23 |
| Pharmaessentia USA Corporation | 1 | $21 |
| Spectrum Pharmaceuticals Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Beigene USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEMPERLI$2,600
- ZEJULA$2,175
- SPY-PHI SYSTEM$349
- myChoice CDx$179
- LYNPARZA$125
How this compares
$8,182 in reported general payments places this provider in the 70th percentile of 26 gynecologic oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 21 | $423,354 |
| LynparzaOlaparib | 45 | $375,439 |
| EliquisApixaban | 73 | $47,711 |
| Gabapentin | 103 | $1,495 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $1,065 |
| Prednisolone Acetate | 19 | $868 |
| Megestrol Acetate | 18 | $725 |
| Scopolamine | 11 | $631 |
| Dexamethasone | 32 | $570 |
| Ondansetron OdtOndansetron | 42 | $440 |
| Anastrozole | 37 | $398 |
| Omeprazole | 15 | $382 |
| Levothyroxine Sodium | 36 | $373 |
| Famotidine | 19 | $333 |
| Letrozole | 15 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $5,004 | $423,35421 claims |
| AstraZenecaLynparza | $748 | $375,43945 claims |
| PfizerEliquis | $70 | $47,71173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 26 gynecologic oncology providers in Arizona.
Other gynecologic oncology in Tucson
- Shobhana TalukdarTucson$4K
- Jillian O'DonnellTucson$1K
- Candice LewisTucson$1K
- Marina MillerTucson$1K
- Alton HallumTucson$1K
- Setsuko ChambersTucson$0
- Lyndsay WillmottPhoenix$448K
- Ivor BenjaminPhoenix$371K
- Mike JanicekScottsdale$88K
- Dennis ScribnerScottsdale$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.